Diamyd Medical signs agreement with Janssen R&D, JDRF and UAB regarding ongoing GABA/GAD-trial

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced
that it has signed an agreement with Janssen Research & Development, the
Juvenile Diabetes Research Foundation (JDRF) and the University of Alabama at
Birmingham regarding the ongoing clinical trial “Effect of GABA or Combination
GABA/GAD on the Progression of Type 1 Diabetes Mellitus in Children”. The
agreement entails that Janssen Research & Development and JDRF will support the
trial with approximately USD 600 000 to be used to study GABA-biomarkers and to
increase the number of patients in the trial.
“The agreement is positive for the trial” says Ulf Hannelius, President and CEO
of Diamyd Medical. “Our in-licensed GABA-technology has been shown to influence
autoimmune and inflammatory diseases in a positive direction when used alone,
and the combination GABA/Diamyd® -vaccine has in a diabetes model shown a strong
synergistic effect in preserving beta cell function. We look with greatest
interest forward to this new collaboration.”

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through
pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy
(ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed
technologies for GABA and Gliadin have also potential to become key pieces of
the puzzle of a future solution to prevent, treat or cure autoimmune diabetes,
and also certain inflammatory diseases. At this time six clinical studies are
ongoing with Diamyd®. Diamyd Medical is one of the major shareholders in the
stem cell company Cellaviva AB. Stem cells can be expected to be used in
Personalized Regenerative Medicine (PRM), for example for restoration of beta
cell mass in diabetes patients where the autoimmune component of the disease has
been arrested. Diamyd Medical also has holdings in the medtech company Companion
Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc.,
Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the
ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.